Get the latest tech news
Eli Lilly's weight loss drug slashes the risk of diabetes in long-term trial
The late-stage trial on tirzepatide also found that patients experienced sustained weight loss over the roughly three-year treatment period.
Eli Lilly's highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with compared with a placebo, according to initial results from a long-term study released Tuesday. The new data also shows the potential long-term health benefits of taking a buzzy class of obesity and diabetes medications called GLP-1s, which mimic hormones produced in the gut to tamp down appetite and regulate blood sugar. "Obesity is a chronic disease that puts nearly 900 million adults worldwide at an increased risk of other complications such as Type 2 diabetes," Dr. Jeff Emmick, senior vice president of product development at Eli Lilly, said in a statement.
Or read this on r/technology